• Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About
Search
Medicines Law & Policy Research and resources on intellectual property and health
  • Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About

Tag: WHA

Invitation: 14 May 2020 – The WHO Covid-19 Technology Pool: The...

Kaitlin Mara - May 12, 2020

Drug Price Transparency Calls Move from South Africa to World Health...

Medicines Law & Policy - May 18, 2019

Recent Posts

  • The European Commission’s proposal for an EU wide compulsory licensing mechanism
  • Updated TRIPS Flexibilities Database
  • New WHO-UNITAID briefing paper: Improving Access to Covid-19 Treatments
  • Protecting Public Health through Technology Transfer: The Unfulfilled Promise of the TRIPS Agreement

Posts by Subject

Abbvie Access to Medicines Access to Vaccines ARIPO AstraZeneca C-TAP Cancer CDCA competition law Compulsory licensing compulsory licensing for export covid-19 Covid-19 Pool Covid-19 vaccine cystic fibrosis Data exclusivity Delinkage DNDi essential medicines list European Commission European Union evergreening Fair Pricing Gilead Hepatitis C human rights IFPMA LDCs market exclusivity Medicines Patent Pool Medicines Pricing Netherlands Orphan Drugs pandemic treaty Patents R&D remdesivir Sofosbuvir The Netherlands transparency TRIPS flexibilities TRIPS Waiver vaccines WHO WTO
Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: office@medicineslawandpolicy.net.
  • Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About
 This work is licensed under Creative Commons.